Bintrafusp alfa
Bintrafusp alfa is a protein pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against programmed cell death 1 ligand 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
58 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 8 | 5 | 1 | — | 1 | 12 |
| Non-small-cell lung carcinoma | D002289 | — | — | 3 | 6 | 1 | — | — | 7 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 2 | 5 | 1 | — | — | 6 |
| Cholangiocarcinoma | D018281 | — | C22.1 | 1 | 3 | 1 | — | — | 4 |
| Biliary tract neoplasms | D001661 | — | C24.9 | — | 3 | 1 | — | — | 3 |
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | — | 2 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 6 | 1 | — | — | — | 6 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 4 | 5 | — | — | — | 6 |
| Triple negative breast neoplasms | D064726 | — | — | 3 | 2 | — | — | — | 4 |
| Anus neoplasms | D001005 | EFO_0003835 | C21 | 3 | 4 | — | — | — | 4 |
| Oropharyngeal neoplasms | D009959 | — | — | 3 | 4 | — | — | — | 4 |
| Prostatic neoplasms | D011471 | — | C61 | 2 | 3 | — | — | — | 3 |
| Melanoma | D008545 | — | — | 2 | 2 | — | — | — | 2 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 2 | — | — | — | 2 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 2 | — | — | — | 2 |
| Sarcoma | D012509 | — | — | 1 | 2 | — | — | — | 2 |
Show 25 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urogenital neoplasms | D014565 | EFO_0003863 | D07 | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal neoplasms | D004938 | — | C15 | — | — | — | — | 1 | 1 |
| Squamous cell neoplasms | D018307 | — | — | — | — | — | — | 1 | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bintrafusp alfa |
| INN | bintrafusp alfa |
| Description | Bintrafusp alfa is a protein pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against programmed cell death 1 ligand 1. |
| Classification | Protein |
| Drug class | fusion proteins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298024 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | NW9K8C1JN3 (ChemIDplus, GSRS) |
Target
Agency Approved
CD274
CD274
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 990 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use